Michael Bruno

Cooley advised Tomorrow Health on its $60 million Series B financing. Tomorrow Health is the developer of a data-driven medical equipment sourcing platform intended to streamline ordering and access to home medical equipment supplies for patients and their families. Partner Sacha Ross led the Cooley team.

Cooley advised Finch Therapeutics on its $127.5 million initial public offering of 7,500,000 shares of common stock. Finch Therapeutics, whose securities now trade on the Nasdaq Global Select Market under the symbol FNCH, is a clinical-stage microbiome therapeutics company. Partners Div Gupta and Ryan Sansom led the Cooley team.

Cooley advised LAVA Therapeutics on its $106.9 million initial public offering of 7,125,712 shares of common stock, which includes the underwriters’ partial exercise of their option to purchase additional shares. LAVA Therapeutics, whose securities now trade on the Nasdaq Global Select Market  under the symbol LVTX, is a biotechnology company focused on transforming cancer treatment by developing a platform of novel bispecific antibodies engineered to selectively induce gamma-delta T-cell-mediated immunity against tumor cells. Partners Christian Plaza, Div Gupta and Josh Kaufman led the Cooley team.

Cooley advised Landos Biopharma on its $100 million initial public offering of 6,250,000 shares of common stock. Landos Biopharma, whose securities now trade on the Nasdaq Global Select Market under the symbol LABP, is a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases. Partners Eric Blanchard, Madison Jones and Div Gupta led the Cooley team.

Cooley advised Lumicks on its $93 million Series D financing round. Partner Eric Blanchard led the Cooley team advising Lumicks, a life sciences tools company that develops equipment used in biology research and immuno-oncology.